Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 11555 Sorrento Valley Road, Suite 203 SAN DIEGO CA 92121 |
Tel: | N/A |
Website: | https://www.aethlonmedical.com |
IR: | See website |
Key People | ||
James B. Frakes Interim Chief Executive Officer, Chief Financial Officer, Senior Vice President - Finance, Company Secretary, Director | Guy F. Cipriani Chief Operating Officer, Senior Vice President | Lee D. Arnold Chief Scientific Officer | Steven P. Larosa Chief Medical Officer |
Business Overview |
Aethlon Medical, Inc. (Aethlon) is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections suppression, seed the spread of metastasis and inhibit the benefit of cancer therapies. The Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression. Hemopurifier helps to bind and clear multiple different glycosylated viruses, such as human immunodeficiency virus (HIV), hepatitis C virus (HCV), Dengue, West Nile, multiple strains of influenza, Ebola, Chikungunya, smallpox, monkeypox, multiple herpes viruses, a MERS-CoV related pseudovirus, and others. Hemopurifier is used as a device for two independent indications: the treatment of individuals with advanced or metastatic cancer and the treatment of life threating viruses that are not approved therapies. |
Financial Overview |
For the nine months ended 31 December 2023, Aethlon Medical, Inc. revenues was not reported. Net loss increased 2% to $9.8M. Higher net loss reflects Payroll and related expenses increase of 33% to $4.2M (expense), Professional Fees increase of 8% to $2.8M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$4.39 to -$3.95. |
Employees: | 15 as of Mar 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $0.57M as of Dec 31, 2023 |
EBITDA (TTM): | -$12.28M as of Dec 31, 2023 |
Net annual income (TTM): | -$12.26M as of Dec 31, 2023 |
Free cash flow (TTM): | -$10.77M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 5,046,538 as of May 15, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |